[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

@article{Azzoli2010AmericanSO,
  title={[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].},
  author={Christopher Azzoli and Sherman Baker and Sarah Temin and William Pao and Timothy B Aliff and Julie Renee Brahmer and David H. Johnson and Janessa L. Laskin and Gregory A Masters and Daniel T. Milton and Luke T Nordquist and David G. Pfister and Steven Piantadosi and Joan Hoff Schiller and Reily Smith and Thomas James Smith and John R. Strawn and David Trent and Guiseppe Giaccone},
  journal={Zhongguo fei ai za zhi = Chinese journal of lung cancer},
  year={2010},
  volume={13 3},
  pages={
          171-89
        }
}
The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non–small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 108 extracted citations

Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges.

Critical reviews in oncology/hematology • 2012
View 4 Excerpts
Highly Influenced

[Targeted agents in the treatment of lung cancer].

Pathologie-biologie • 2012
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 232 references

Erlotinib in previously treated non-small-cell lung cancer.

The New England journal of medicine • 2005
View 10 Excerpts
Highly Influenced

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2004
View 7 Excerpts
Highly Influenced

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 13 Excerpts
Highly Influenced

Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study

T Ciuleanu, T Brodowicz, CP Belani
J Clin Oncol 26:426s, 2008 • 2008
View 15 Excerpts
Highly Influenced

Pack years of cigarette smoking as a predictor of survival in 2,013 patients with stage IIIb/IV non-small cell lung cancer (NSCLC)

YY Janjigian
J Clin Oncol 26:425s, 2008
View 19 Excerpts
Highly Influenced

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

Annals of oncology : official journal of the European Society for Medical Oncology • 2007
View 7 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…